로그인 회원가입
icon_bulk_order대량 주문 조회 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: > BAFF

BAFF

요약

Name:B-cell-activating factor/B lymphocyte stimulator
Target Synonym:Dendritic Cell-Derived TNF-Like Molecule,B-Cell-Activating Factor,CD257,Epididymis Secretory Sperm Binding Protein,Tumor Necrosis Factor-Like Protein ZTNF4,Delta4 BAFF,BAFF,THANK,BLYS,ApoL Related Ligand TALL-1,TNF Superfamily Member 13b,Delta BAFF,TALL-1,Tumor Necrosis Factor Ligand 7A,B-Cell Activating Factor,B Lymphocyte Stimulator,B-Lymphocyte Stimulator,TNF And ApoL-Related Leukocyte Expressed Ligand 1,ZTNF4,Tumor Necrosis Factor (Ligand) Superfamily, Member 20,TNF- And APOL-Related Leukocy
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:3
Lastest Research Phase:Approved

제품 리스트 비교 또는 구매

일부의 생물활성 데이터

BAF-H52D4-Cell-based assay
Human FcRn Heterodimer Protein Cell_Base

Human BAFF, His,Flag Tag, active trimer (Cat. No. BAF-H52D4) stimulates proliferation of mouse spleen cells. The EC50 for this effect is 1.97-2.90 ng/mL (Routinely tested).

BAF-H5261-Cell-based assay
Human FcRn Heterodimer Protein Cell_Base

Human BAFF, Fc Tag, active trimer (Cat. No. BAF-H5261) stimulates proliferation of mouse spleen cells. The EC50 for this effect is 4.91-9.81 ng/mL (Routinely tested).

BAF-H52D4-SPR
Human_FcRn_Heterodimer_Protein_SPR

Human BAFFR Protein, Fc Tag (Cat. No. BAR-H5257) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human BAFF Protein, His,Flag Tag (Cat. No. BAF-H52D4) with an affinity constant of 5.54 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

BAF-H5261-SPR
Human_FcRn_Heterodimer_Protein_SPR

Immobilized Human BAFF, Fc Tag, active trimer (Cat. No. BAF-H5261) on CM5 Chip can bind Human TACI/TNFRSF13B, Fc Tag (Cat. No. TAI-H5256) with an affinity constant of 0.658 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

Synonym Name

TNFSF13B,BAFF,BLYS,CD257,DTL,TALL1,THANK,TNFSF20,ZTNF4,TALL-1

Background

B-cell activating factor (BAFF) is also known as tumor necrosis factor ligand superfamily member 13B , TNFSF13B, BAFF, B Lymphocyte Stimulator (BLyS) , cluster of differentiation 257 (CD257), DTL, TNF- and APOL-related leukocyte expressed ligand (TALL-1), THANK, TNFSF20, ZTNF4, and is a  cytokine that belongs to the tumor necrosis factor (TNF) ligand family. This cytokine is a ligand for receptors TNFRSF13B/TACI, TNFRSF17/BCMA, and TNFRSF13C/BAFFR. This cytokine is expressed in B cell lineage cells, and acts as a potent B cell activator. It has been also shown to play an important role in the proliferation and differentiation of B cells. It is expressed as transmembrane protein on various cell types including monocytes, dendritic cells and bone marrow stromal cells. BAFF is the natural ligand of three unusual tumor necrosis factor receptors named BAFF-R, TACI, and BCMA, all of which have differing binding affinities for it. These receptors are expressed mainly on mature B lymphocytes (TACI is also found on a subset of T-cells and BCMA on plasma cells). TACI binds worst since its affinity is higher for a protein similar to BAFF, called a proliferation-inducing ligand (APRIL). BCMA displays an intermediate binding phenotype and will work with either BAFF or APRIL to varying degrees. Signaling through BAFF-R and BCMA stimulates B lymphocytes to undergo proliferation and to counter apoptosis. All these ligands act as heterotrimers (i.e. three of the same molecule) interacting with heterotrimeric receptors, although BAFF has been known to be active as either a hetero- or homotrimer. BAFF acts as a potent B cell activator and has been shown to play an important role in the proliferation and differentiation of B cells. 

Clinical and Translational Updates

Related Molecule

공개 약품 정보

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Belimumab BmAb; HGS-1006; GSK-1550188 Approved Glaxosmithkline Plc Benlysta, 倍力腾 Mainland China Lupus Nephritis Glaxosmithkline (China) Investment Co Ltd 2011-03-09 Lupus Nephritis; Lupus Erythematosus, Systemic Details
Telitacicept RCT-18; RC-18; RCT18; RC18 Approved RemeGen Co Ltd 泰爱 Mainland China Lupus Erythematosus, Systemic RemeGen Co Ltd 2021-03-09 Myasthenia Gravis; Multiple Sclerosis, Relapsing-Remitting; Glomerulonephritis, IGA; Arthritis, Rheumatoid; Sjogren's Syndrome; Multiple Sclerosis; Neuromyelitis Optica; Lupus Erythematosus, Systemic Details

임상 약품 정보

Name Research Code Research Phase Company Indications Clinical Trials
UBP-1213 UBP-1213 Phase 1 Clinical Wuhan Huaxin Kangyuan Biomedicine Co Ltd, Shanghai Junshi Biosciences Co Ltd Lupus Erythematosus, Systemic Details
Blisibimod A-623; AMG-623 Anthera Details
hCBE-11 hCBE-11 Biogen Inc Details
Rozibafusp alfa AMG-570; MEDI-0700 Phase 1 Clinical Amgen Inc Lupus Erythematosus, Systemic Details
Tabalumab LY-2127399 Phase 2 Clinical Eli Lilly And Company Multiple Sclerosis, Relapsing-Remitting; Dermatomyositis; Arthritis, Rheumatoid; Autoimmune Diseases; Scleroderma, Systemic; Multiple Myeloma; Connective Tissue Diseases; Arthritis, Juvenile; Multiple Sclerosis; Lupus Erythematosus, Systemic; Kidney Failure, Chronic; Pemphigus Details
Atacicept TACI-Ig Phase 2 Clinical Zymogenetics Glomerulonephritis, IGA; Arthritis, Rheumatoid; Multiple Sclerosis; Optic Neuritis; Lupus Nephritis; Lupus Erythematosus, Systemic Details

This web search service is supported by Google Inc.

totop